Brief: Polarityte Announces U.S. FDA Approval Of IND For Pivotal Phase 3 Study Of Skinte® For Chronic Cutaneous Ulcer
18/01/2022 13:17
Jan 18 (Reuters) - PolarityTE Inc PTE.O :
* POLARITYTE ANNOUNCES U.S. FDA APPROVAL OF IND FOR PIVOTAL
PHASE
3 STUDY OF SKINTE® TO SUPPORT CHRONIC CUTANEOUS ULCER INDICATION
Source text for Eikon: ID:nPn2LVKvka
Further company coverage: PTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RegenETP,
See all newsBrief: PolarityTE Receives Delisting Notice From Nasdaq
U.S. STOCKS ON THE MOVE-Biogen, Phoenix Motor, Mastercard
U.S. STOCKS ON THE MOVE-Energy sector, Affirm, Stitch Fix
U.S. STOCKS ON THE MOVE-Shutterstock, Salesforce, Plug Power
Brief: Polarityte And Its Subsidiaries Files Voluntary Petitions For Relief Under Chapter 11